Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Suplee

Vascular Surgery Sarasota, FL Medical Doctor

NPI 1013232289 CMS profile 1373892

3333 Cattlemen Rd Ste 206, Sarasota, FL 34232

Open in the dashboard

General payments

$63,862

235 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Suplee of Sarasota, FL is reported in the CMS Open Payments database as having received $63,862 across 235 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,241 45
2024 General $6,878 31
2023 General $1,323 29
2022 General $29,116 51
2021 General $14,082 29
2020 General $738 21
2019 General $2,483 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Suplee
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Ryan Suplee were reported at $9,241. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Ryan Suplee Vascular Surgery median Middle half National median
2019 $2,483 $796 $226–$2,363 $163
2020 $738 $348 $118–$1,110 $114
2021 $14,082 $471 $158–$1,421 $132
2022 $29,116 $725 $222–$2,183 $149
2023 $1,323 $836 $257–$2,440 $160
2024 $6,878 $909 $252–$2,619 $164
2025 $9,241 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alphatec Spine, Inc $53,278 32 payments
  2. Silk Road Medical, Inc. $2,397 27 payments
  3. W. L. Gore & Associates, Inc. $1,640 26 payments
  4. Penumbra, Inc. $1,175 26 payments
  5. Boston Scientific Corporation $1,134 27 payments
  6. Medtronic Vascular, Inc. $818 17 payments
  7. NuVasive, Inc. $692 6 payments
  8. Philips Electronics North America Corporation $611 20 payments
  9. CVRx, Inc. $549 7 payments
  10. Medtronic, Inc. $507 13 payments
  11. Other $1,061 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $39,000 7 payments
  2. Travel and Lodging $15,455 31 payments
  3. Food and Beverage $9,406 197 payments
Products named General payments · program years 2019–2025
  1. Solus ALIF $35,473 12 payments
  2. Other - Miscellaneous $16,850 16 payments
  3. ENROUTE Transcarotid Stent $1,693 22 payments
  4. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,693 22 payments
  5. ELUVIA $956 18 payments
  6. Indigo System $923 18 payments
  7. Endurant $818 17 payments
  8. ENROUTE 0.014 Guidewire $704 5 payments
  9. ENROUTE Transcarotid Stent System $704 5 payments
  10. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $704 5 payments
  11. Other $7,884 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

530

Median for Vascular Surgery: 122

Drug cost

$157,892

Median for Vascular Surgery: $14,135

Branded share of claims

85.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 132 $131,288
Xarelto Rivaroxaban Brand 17 $23,679
Clopidogrel Clopidogrel Bisulfate Brand 276 $2,189
Gabapentin Generic 30 $233
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 26 $202
Cilostazol Generic 14 $183
Atorvastatin Calcium Generic 24 $111
Furosemide Generic 11 $6

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 131 billing codes

Paid by Medicare

$522,870

Medicare's payments for the services billed

Medicare patients

1,260

Average age 77

Services billed

3,524

607 women, 653 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 48%
Diabetes 28%
Chronic kidney disease 26%
Atrial fibrillation 25%
COPD 20%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

235 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record